{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:28:32Z","timestamp":1772126912398,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.127082","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T01:57:59Z","timestamp":1743991079000},"page":"127082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10\u201360\u00a0years old"],"prefix":"10.1016","volume":"53","author":[{"given":"Guifan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouchun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bidan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leitai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2025.127082_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/tropicalmed2020005","article-title":"Four thousand years of concepts relating to rabies in animals and humans, its prevention and its cure","volume":"2","author":"Tarantola","year":"2017","journal-title":"Tropical Medicine and Infectious Disease"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127082_bb0010","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/v13071252","article-title":"The route of Administration of Rabies Vaccines: comparing the data","volume":"13","author":"Briggs","year":"2021","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127082_bb0020","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00829-21","article-title":"Toll-like receptor 4 regulates rabies virus-induced humoral immunity through recruitment of conventional type 2 dendritic cells to lymph organs","volume":"95","author":"Chen","year":"2021","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127082_bb0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/21645515.2014.995059","article-title":"Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen)","volume":"11","author":"Bj","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127082_bb0030","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/21645515.2017.1279770","article-title":"Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects","volume":"13","author":"Shi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127082_bb0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/hv.7.2.14003","article-title":"The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen","volume":"7","author":"Liu","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2025.127082_bb0040","series-title":"The standard guidelines for adverse reactions grading of vaccine clinical trials","author":"Food","year":"2005"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127082_bb0045","doi-asserted-by":"crossref","first-page":"e0004874","DOI":"10.1371\/journal.pntd.0004874","article-title":"Human rabies in China, 1960-2014: a descriptive epidemiological study","volume":"10","author":"Zhou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127082_bb0050","series-title":"Face sheets. Rabies. Rabies (who.int)","author":"World Health Organization","year":"2025"},{"issue":"0","key":"10.1016\/j.vaccine.2025.127082_bb0055","first-page":"8","article-title":"Novel approaches to the prevention and treatment of rabies","volume":"0","author":"Gnanadurai","year":"2015","journal-title":"International journal of virology studies & research"},{"issue":"50","key":"10.1016\/j.vaccine.2025.127082_bb0060","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2013.10.043","article-title":"A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab\u00ae when administered according to a post-exposure regimen in healthy children and adults in China","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127082_bb0065","series-title":"WHO Expert Consultation on Rabies: third report","author":"World Health Organization","year":"2018"},{"issue":"21","key":"10.1016\/j.vaccine.2025.127082_bb0070","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1016\/j.vaccine.2011.03.048","article-title":"Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)","volume":"29","author":"Fayaz","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127082_bb0075","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: a post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127082_bb0080","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4161\/hv.28420","article-title":"Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China","volume":"10","author":"Quan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127082_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2211896","article-title":"Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10\u201350 years old: randomized, blinded, parallel controlled phase III clinical study","volume":"19","author":"Huang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127082_bb0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/cid\/ciy513","article-title":"Preexposure intradermal rabies vaccination: a noninferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days","volume":"68","author":"Soentjens","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127082_bb0095","first-page":"1","article-title":"WHO Expert Consultation on Rabies: second report","volume":"982","author":"World Health Organization","year":"2013","journal-title":"World Health Organization technical report series"},{"key":"10.1016\/j.vaccine.2025.127082_bb0100","series-title":"Rabies vaccines and immunoglobulins: WHO position Summary of 2017 updates. 2018 Rabies vaccines and immunoglobulins: WHO position Summary of 2017 updates","author":"World Health Organization","year":"2025"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:26:04Z","timestamp":1745130364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25003792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"alternative-id":["S0264410X25003792"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127082","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10\u201360\u00a0years old","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127082"}}